# US 2012/0251534 A1 · Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251534 A1
- Document ID: US20120251534A1
- Status: Published application
- Kind: A1
- Application number: 13/524,800
- Filed: 2012-06-15
- Published: 2012-10-04
- Earliest claimed: 1998-08-11
- Inventors: Antonio J. Grillo-Lopez
- Web page: https://patentgrep.com/patent/US20120251534A1

## CPC

- C07K 16/2887: {against CD20}
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/2013: {IL-2}
- A61K 38/212: {IFN-alpha}
- A61K 38/217: {IFN-gamma}
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/1069: {the tumor cell being from blood cells, e.g. the cancer being a myeloma}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C02F 1/003: {using household-type filters for producing potable water, e.g. pitchers, bottles, faucet mounted devices (C02F9/20 takes precedence)}
- C07K 16/3061: {Blood cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C02F 2307/02: as part of a bottle
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/77: Internalization into the cell
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C02F: TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE (separation in general B01D; special arrangements on waterborne vessels of installations for treating water, waste water or sewage, e.g. for producing fresh water, B63J; adding materials to water to prevent corrosion C23F; treating radioactively-contaminated liquids G21F9/04; regeneration of reactants for recirculation into processes, see the relevant places for the processes)

## Abstract

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.

## Claims

### Claim 1

A method of treating rituximab-refractory B-cell non-Hodgkin's lymphoma, comprising administering an anti-CD20 antibody to a patient in an amount effective to treat the lymphoma.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the antibody comprises human constant regions.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the antibody is humanized.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the non-Hodgkin's lymphoma is low grade or follicular lymphoma.
